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Abstract: Endophthalmitis is a rare but sight-threatening complication that can occur after 
ocular surgery or trauma or as a consequence of systemic infection. To optimize visual outcome, 
early diagnosis and treatment are essential. Over recent decades, advances in hygienic stan-
dards, improved microbiologic and surgical techniques, development of powerful antimicrobial 
drugs, and the introduction of intravitreal antibiotic therapy have led to a decreased incidence 
and improved management of endophthalmitis. However, endophthalmitis still represents a 
serious clinical problem. This review focuses on current principles and techniques for evalua-
tion and treatment of endophthalmitis. In addition, it addresses recent developments regarding 
antimicrobial treatment and prophylaxis of infectious endophthalmitis.
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Introduction
Endophthalmitis is one of the most devastating diagnoses in ophthalmology. It is a 
serious intraocular inflammatory disorder affecting the vitreous cavity that can result 
from exogenous or endogenous spread of infecting organisms into the eye.1 With 
any breaching of the ocular bulbus, the potential exists for introducing an infectious 
inoculum large enough to cause an intraocular infection. This is most commonly seen 
after intraocular surgery but can also occur as a complication of penetrating ocular 
trauma or from the adjacent periocular tissues.
Endogenous endophthalmitis is less common and occurs secondary to hematog-
enous dissemination and spread from a distant infective source in the body. In patients 
with endogenous endophthalmitis, predisposing risk factors usually exist.2–6
In most cases, independent of its origin, the presentation of endophthalmitis consists 
of reduced or blurred vision, red eye, pain, and lid swelling.3,5,7,8 Progressive vitritis is 
one of the key findings in any form of endophthalmitis, and in nearly 75% of patients 
a hypopyon can be seen at the time of presentation1 (see Figure 1). Progression of the 
disease may lead to panophthalmitis, corneal infiltration, and perforation, affection 
of orbital stuctures, and phthisis bulbi.
In general, the incidence of endophthalmitis has decreased in recent decades9 
and, fortunately, endophthalmitis is rare.7,9,10 Nonetheless, its evident severity and 
indistinct prognosis require timely and effective treatment to provide satisfactory 
visual results.Clinical Ophthalmology 2010:4 122
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Pathogenesis and clinical 
presentation
Exogenous endophthalmitis
Postoperative endophthalmitis
Endophthalmitis after ocular surgery is the most common 
form of the condition. Cataract surgery is by far the most 
frequently performed intraocular surgery.11 Approximately 
90% of postoperative endophthalmitis cases develop after 
this procedure7,9,10 with an incidence following such surgery 
ranging from 0.08% to 0.7%.10,12–15 A recently published 
meta-analysis indicates that the endophthalmitis rate seems 
to have increased during the last two decades.16 According 
to these data, the rate of endophthalmitis following cata-
ract surgery was about 0.09% during the 1990s and 0.27% 
in 2000.16 Greater use of clear corneal incision has been 
debated as a potential reason for this. Experimental data 
indicate that with this technique wound architecture seems 
to be less stable, thus allowing fluctuations in the intraocular 
pressure and potentially easier entry of bacteria through a 
less completely sealed wound. Some studies found a three- 
to four-fold risk for endophthalmitis after clear cornea 
cataract surgery compared with scleral tunnel incisions.17,18 
In contrast, Lalwani et al reviewed 73 endophthalmitis cases 
after clear cornea cataract surgery and compared them with 
the data from the Endophthalmitis Vitrectomy Study (EVS), 
in which scleral tunnel and clear cornea incisions were used. 
They found that time to endophthalmitis diagnosis was longer 
in clear cornea cataract surgery cases but clinical features, 
causative organisms, and visual acuity outcomes were similar 
to those reported in the EVS.19
Wound integrity also seems to be an important feature 
influencing the risk for developing endophthalmitis in pars 
plana vitrectomy. In general, the incidence of endophthal-
mitis after pars plana vitrectomy is low (0.03%–0.05%).10,20 
Nevertheless, recent data indicate that the use of sutureless 
small incision techniques (eg, 23- or 25-gauge incision size) 
is significantly associated with a higher rate of postoperative 
endophthalmitis than the sutured 20-gauge technique.21
However, endophthalmitis can also complicate other ocular 
surgeries and procedures such as intravitreal injections.22,23 
Some data suggest that penetrating keratoplasty, trabecu-
lectomy, and glaucoma drainage device implantation have 
a higher risk of being complicated by endophthalmitis than 
cataract surgery.24–26 Regarding glaucoma filtering surgery, 
Figure 1 Anterior chamber inflammation, mild corneal edema, and hypopyon in bacterial endophthalmitis.Clinical Ophthalmology 2010:4 123
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endophthalmitis is reported to occur after 0.2%–9.6% of 
trabeculectomies,24,27–32 and its incidence seems to increase 
with the rising use of antifibrotic agents, such as mitomycin-
C or 5-fluorouracil.27–29,32,33 Endophthalmitis rarely occurs 
after external ocular surgeries including scleral buckling, 
pterygium excision, removal of corneal sutures, and stra-
bological interventions.34–38
In general, secondary intraocular lens placement seems 
to be associated with the highest risk for developing endo-
phthalmitis (0.2%–0.37%) and pars plana vitrectomy with 
the lowest (0.03%–0.05%).10,20
Preoperative risk factors include eyelid abnormalities, 
blepharitis, conjunctivitis, cannuliculitis, lacrimal duct 
obstructions, contact lens wear, and ocular prosthesis in the 
fellow orbit.39–42
The ocular surface and the adnexa are considered the 
primary sources of infection in postoperative endophthalmi-
tis.41 However, contaminated agents or surgical equipment 
used perioperatively may also be a source of infection.43–45 In 
addition, perioperative variations seem to have some impact 
on postoperative endophthalmitis rate; different intraocular 
lens (IOL) materials potentially act as vectors for bacterial 
spread into the eye11,46,47 and viscoelastic substances, such as 
sodium hyaluronate, or hydroxypropylmethylcellulose may 
facilitate transmission of bacteria to the eye.48,49
Knowledge about the cause of endophthalmitis is essential 
because the spectrum of organisms may change, warranting 
different therapeutic approaches. Bacteria infections are the 
most common cause of postoperative endophthalmitis, and 
Gram-positive isolates account for most cases.7,10,15,50 Fungal 
infections may also occur, particularly in association with the 
use of contaminated ocular irrigation fluids.43,51
Postoperative endophthalmitis can be either sterile or 
infectious. In the EVS, only 69.3% of cases met the criteria 
for laboratory-confirmed infection.7 The reasons that more 
than 30% of cases failed to obtain positive results from cul-
ture vary and include low microbial counts, spontaneously 
sterilizing during the ocular inflammatory response of certain 
strains (eg, Staphylococcus epidermidis), or even noninfec-
tious inflammations.7,10,15,50,52
In addition, the etiology of endophthalmitis might differ 
depending on the location in the world where the disease 
occurs. Whereas the microbiologic spectrum in Europe or in 
the US seems to be generally comparable,7,46 it might be very 
different in other parts of the world. According to the EVS, 
94.2% of culture-positive endophthalmitis cases involved 
Gram-positive bacteria; 70% of isolates were Gram-positive, 
coagulase-negative staphylococci, 9.9% were Staphylococcus 
aureus, 9.0% were Streptococcus species, 2.2% were Entero-
coccus species, and 3% were other Gram-positive species. 
Gram-negative species were involved in 5.9% of cases.7 
In contrast, a recent survey from India reported that Gram-
positive bacteria accounted for only 53% of postoperative 
endophthalmitis cases, but 26% were Gram-negative isolates 
and 17% were of fungal origin.53
The advent of new therapeutic strategies for treating 
age-related macular degeneration, diabetic macular edema, 
and uveitis has led to a dramatic increase in intravitreal drug 
application. The risk of endophthalmitis after intravitreal 
injection is of rising concern.23 Recent data, albeit limited, 
indicate that coagulase-negative staphylococci, as in post-
operative endophthalmitis, appear to be the predominant 
pathogens in the development of endophthalmitis after 
intravitreal injection.23 Less common organisms, including 
Streptobacillus parasanguis, Mycobacterium chelonae, 
and Streptobacillus species, as well as cases of noninfec-
tious (sterile) endophthalmitis, especially in the context of 
intravitreal triamcinolone acetonide injections, have been 
reported in the literature.22,23,54
The majority of patients with postoperative endophthalmitis 
present with an acute onset and within seven days after 
  surgery.7,55 Chronic postoperative endophthalmitis is charac-
terized by insidious inflammation and appears less common 
than the acute variety. Such cases can occur in the early 
postoperative period but usually manifest several weeks or 
month after surgery and often include less virulent bacteria 
and fungal pathogens.
Depending on the infecting organism, a correlation is 
thought to exist between clinical presentation and micro-
biologic spectrum. Gram-positive, coagulase-negative 
micrococci seem to cause less severe infections compared 
with more virulent Gram-negative and “other” Gram-positive 
organisms.7 Streptococcal endophthalmitis often results in 
earlier onset and notably worse outcomes than infections 
by staphylococcal species. Endophthalmitis cases that failed 
to obtain positive results from culture tended to have a later 
onset and a better visual outcome.55–59
More severe infections are correlated with loss of red fundus 
reflex, afferent papillary defect, and light perception only at the 
time of initial presentation.7 The presence of corneal infiltrates 
or cataract wound abnormalities are more strongly associated 
with more virulent Gram-negative and “other” Gram-positive 
organisms.7 In addition, when more virulent pathogens are 
involved, signs and symptoms of endophthalmitis might be 
apparent earlier.7 This is important because these cases seem 
to be significantly correlated with a worse visual outcome.Clinical Ophthalmology 2010:4 124
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Specific factors influencing bacterial adhesion, including 
IOL material and surface irregularities, might have a role in the 
development of certain forms of endophthalmitis. S epidermidis 
carrying the intercellular adhesion locus might play a part in the 
pathogenesis of some forms of endophthalmitis.60,61
In most cases the diagnosis of endophthalmitis is made 
on clinical grounds. Any eye with inflammation that is out of 
proportion to the previous surgical trauma or greater than the 
predicted postoperative clinical course must be suspected as 
indicating postoperative endophthalmitis. If doubt cannot be 
erased, frequent observations should be conducted until the 
clinical course can be determined. Symptoms can be variable, 
from very little inflammation in the anterior chamber and the 
anterior portion of the vitreous to extremely painful panop-
thalmitis with no fundus view, corneal edema, or complete 
anterior chamber hypopyon7,24,50 (see Figure 2).
According to the EVS, hypopyon can be seen in nearly 
75% of patients, whereas ocular pain, often regarded as pathog-
nomonic for endophthalmitis, was absent in 25% of patients.7 
In the European Society of Cataract and Refractive Surgeons 
Endophthalmitis Study (ESCRS) of prophylaxis for postoperative 
endophthalmitis after cataract surgery, hypopyon was present in 
80% of culture-proven cases and 56% of unproven cases, result-
ing in an overall incidence of 72%.55 Most common presentations 
include decreased vision, ocular pain and redness, corneal edema, 
and vitritis. In addition, retinal vasculitis, retinal hemorrhages, and 
posterior pole hypopyon may occur7,24,50 (see Figure 3).
Posttraumatic endophthalmitis
Endophthalmitis is an important complication of open globe 
injury. About 25% of endophthalmitis cases are a result of 
ocular trauma and these are more often associated with a 
poorer visual outcome than otherwise similar globe injuries.8 
After posttraumatic endophthalmitis, only 22% to 42% of 
patients obtain a final visual acuity of 20/400 or better.62–64
The risk for developing endophthalmitis after sustaining 
open globe injuries is estimated at about 7%.1,8,65 Increasing 
risk factors for endophthalmitis after ocular injury are dirty 
wound, lens capsule rupture, older age, initial presentation 
with a delay of more than 24 hours, and the presence of intra-
ocular foreign bodies.8,66–69 The incidence of endophthalmitis 
in cases of penetrating ocular trauma has been reported to 
range from 3.3% to 30% and after intraocular foreign body 
from 1.3% to 61%.8,63
A recent study from China, including 4968 eyes with 
open globe injury, found an incidence of posttraumatic 
endophthalmitis of 11.9%,70 which is consistent with previ-
ous published data within the range of 2.6% to 54.2%.70–73 
In contrast, no evident correlation is found between the 
results of intraocular content culturing and development 
of posttraumatic endophthalmitis. Ariyasu and colleagues 
found that 33% of open globe injuries were culture-positive 
when aqueous was sampled, but none of these patients 
developed endophthalmitis.66 In contrast, the prevalence of 
culture-negative cases of posttraumatic endophthalmitis has 
Figure 2 Leukocornea as a result of massive corneal edema and complete hypopyon in advanced Staphylococcus aureus endophthalmitis.Clinical Ophthalmology 2010:4 125
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been reported to range from 17% to 42%.67,68,74–76 Therefore, 
some authors do not suggest routine culture in all cases of 
open globe injury.67
Bacillus and Streptococcus are common species found in 
penetrating trauma with an intraocular foreign body.68 This is 
important because Bacillus species are associated with more 
aggressive infection and are especially common in intraocular 
foreign bodies with organic composition.64 Other species 
isolated include S. epidermidis, Propionibacterium acnes, 
Pseudomonas and Streptococcus species, Gram-negative 
organisms, fungi, and mixed pathogens.8,64,70
Initial evaluation of posttraumatic endophthalmitis must 
exclude occult or retained foreign bodies. If the fundus 
view is inadequate, computed tomography or, in eyes with 
self-sealing or previously sutured wounds, ultrasound may 
be helpful. Magnetic resonance imaging must be avoided 
because a retained foreign body might be magnetic.
Posttraumatic endophthalmitis may also be a result 
of contagious spread from an infected corneal, scleral, or 
  adjacent wound.8,68–70 Depending on the virulence of the 
infecting organism, posttraumatic endophthalmitis may occur 
within hours after the trauma or up to several weeks after 
injury.8,68–70 Signs and symptoms must be evaluated with 
regard to the degree of traumatic injury and include decreased 
vision, pain greater than expected, lid swelling, corneal ring 
ulcer, anterior chamber inflammation, hypopyon, vitritis, or 
frank purulence.
Endogenous endophthalmitis
Unlike the origin in exogenous endophthalmitis, where 
the pathogen enters from outside the body into the eye, in 
endogenous endophthalmitis the infection is secondary to 
hematogenous spread from a distant infective source within 
the body. The endogenous form of endophthalmitis accounts 
Figure 3 Posterior hypopyon in bacterial endophthalmitis imaged with Optomap widefield fundus imaging.Clinical Ophthalmology 2010:4 126
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for approximately 5% to 10% of endophthalmitis cases.3,4,77–80 
It occurs when microorganisms in the bloodstream get into 
the eye, cross the blood–retina barrier, and infect the ocular 
tissue. Because of the higher blood flow, choroids and cili-
ary body are the primary focuses of infection in the eye with 
secondary involvement of the retina and vitreous.3,5,79,81
Risk factors for the development of endogenous endo-
phthalmitis are mainly related to immunosuppression or to 
procedures that increase the risk for blood-borne infections. 
Most common factors include immunosuppressive diseases, 
such as diabetes mellitus, HIV infection, cancer, renal 
failure requiring dialysis, cardiac disease, long-term use of 
broad-spectrum antibiotics, steroids and other immunosup-
pressive drugs, major surgery, especially intra-abdominal 
surgery, intravenous hyperalimentation, indwelling intra-
venous catheters, and intravenous drug abuse.3,4,77–80 Liver 
abscesses have been reported as the most common infectious 
origin,3,82–84 followed by pneumonia, endocarditis, soft tissue 
infection, urinary tract infections, meningitis, septic arthritis, 
and orbital cellulitis.3
Causative organisms of endogenous endophthalmitis 
may be bacteria, as well as fungi, and rarely parasites. In 
contrast to exogenous forms of this disease, in endogenous 
endophthalmitis fungal pathogens play an important role.3,4,85 
However, the infecting organisms vary with geographic 
location.
In Europe and the US, Streptococcus species, S. aureus, 
and other Gram-positive bacteria account for two-thirds 
of bacterial endogenous endophthalmitis cases and Gram-
negative isolates are found in only 32% of cases.4,79 These 
numbers differ significantly from East Asia, where most 
cases of endogenous endophthalmitis are caused by Gram-
negative organisms. In these areas, Klebsiella isolates count 
for 80% to 90% of positive cultures.3,83 This difference 
might be attributable to the higher incidence of cholan-
giohepatitis and liver abscess in East Asian people than in 
the Western population.3,82–84 However, during the last two 
decades, the number of endogenous ocular infections due to 
Gram-negative pathogens has dramatically increased in the 
Western world.79 In contrast with its prominent role in acute 
postoperative endophthalmitis, S. epidermidis is only rarely 
found to cause endogenous endophthalmitis.3
Fungal endophthalmitis has become an increasing issue in 
western countries. Candida albicans followed by Aspergillus 
are the predominant species.3,85 Candida species are a part of 
the human flora where they exist as commensals on the muco-
sal surface of the respiratory, gastrointestinal, and female 
genital tracts.86 Where the immune system is compromised 
these organisms potentially become pathogenic. Candida 
species are the most common cause of nosocomial fungal 
infections.87–89
Candida chorioretinitis and endophthalmitis occur 
predominantly as a result of candidemia seeding the eye; 
cases in otherwise healthy individuals have rarely been 
reported.90,91 Prospective studies demonstrated that patients 
with candidemia have a risk of developing endogenous fungal 
endophthalmitis of up to 49%.2,81,92,93 However, a recently 
published study demonstrated that in patients with dissemi-
nated fungal disease, Candida chorioretinitis and endophthal-
mitis occurred in approximately 2.5% of cases.94 These data 
might indicate that the current trend for prophylaxis and 
early treatment, as well as new drugs and treatment strate-
gies for Candida infections, have decreased the incidence of 
fungal ocular complications dramatically.94,95 Other isolates 
commonly found in endogenous fungal endophthalmitis are 
Cryptococcus and Fusarium species.85,90
Clinical findings in endogenous endophthalmitis may 
be similar to those in infections of exogenous origin. They 
include decreased vision, ocular pain, conjunctiva injection, 
hypopyon, corneal edema, vitritis, and reduced fundus view 
secondary to inflammation. Especially in cases of fungal 
infection, a subacute onset of floaters and blurred vision may 
be associated with ocular discomfort and photophobia.94 In 
Candida infections, localized fluffy creamy white retinal or 
subretinal nodules may be associated with vitreous haze.86,94 
(see Figure 4). Early or peripheral fungal lesions may be 
asymptomatic, with patient referral for ocular consultation 
based on a positive blood culture or diagnosis of a systemic 
fungal infection. When more virulent pathogens are involved, 
widespread areas of perivascular infiltrates and hemor-
rhages with necrosis and retinal infarction can be seen.5,8,96,97 
In panophthalmitis, the whole globe and the orbital tissue 
may be involved.5,84
Management and perspectives
The prognosis of endophthalmitis, whether of exogenous or 
endogenous origin, is often poor. In general, endophthalmitis 
is recognized as an ominous disease, which runs a potentially 
devastating course, leaving only very limited visual function 
in many patients. Therefore, early diagnosis and treatment 
with antimicrobial therapy are fundamental to optimize visual 
outcome. In addition, the anticipated rise in ocular surgeries, 
as well as growing evidence that the rates of postoperative 
endophthalmitis might increase, underscore the importance 
of identifying effective methods of prophylaxis for improving 
surgical safety.Clinical Ophthalmology 2010:4 127
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If endophthalmitis occurs, in most cases the diagnosis is 
based on clinical findings. Therapy is usually initiated empiri-
cally while microbiologic testing is being performed.
Early intervention is required and justified. With the intro-
duction of intraocular sampling and intravitreal injection of 
antimicrobial agents, as well as the possibility for vitrectomy, 
management of endophthalmitis has entered a new era. The 
availability of such an armamentarium allows better manage-
ment of endophthalmitis. However, knowledge about the likely 
organism that causes endophthalmitis, as well as the antimicro-
bial drug apt to be most effective, remains paramount.
Exogenous endophthalmitis
Historically, treatment of exogenous endophthalmitis was 
consisted mainly of intravenous antibiotics.1 Nevertheless, 
most systemically administered antibiotics do not reach 
  sufficiently high intraocular concentrations for effective 
  treatment of severe intraocular infections such as endophthal-
mitis. A more effective way to achieve a high concentra-
tion of an antimicrobial substance within the eye and the 
infected tissue is intravitreal drug application. Therefore, the 
intravitreal injection of antibiotics has become the primary 
method of administration in the treatment of exogenous 
endophthalmitis.1,98,99
Unless there is no other unequivocal result from cultur-
ing, endophthalmitis therapy should cover Gram-positive 
organisms, which play a predominant role in exogenous 
endophthalmitis. Gram-negative coverage is also important 
because these organisms are associated with higher virulence 
and poorer outcome.
Current antibiotic standard protocols for intravitreal 
application are empirically based and include the peptide anti-
biotic vancomycin (1.0 mg/0.1 mL) for Gram-positive cover-
age,7 in combination with the β-lactam antibiotic ceftazidime 
(2.25 mg/0.1 mL) for Gram-negative coverage.7 In patients 
sensitive to β-lactam drugs, amikacin (400 µg/0.1 mL), an 
aminoglycoside antibiotic, might be considered instead of 
ceftazidime. However, a degree of retinal toxicity of amikacin 
has been reported.100,101
Gram-positive organisms reportedly have a 99% sus-
ceptibility to vancomycin.102 Consequently, it has become a 
valuable component of endophthalmitis treatment. However, 
recently cases of vancomycin-resistant strains in endophthal-
mitis have been reported,103,104 and emerging resistance of 
Gram-positive pathogens to vancomycin is a concern.105,106 
In addition, the EVS showed that only 89.5% of Gram-
  negative isolates were sensitive to amikacin or ceftazidime;7 
in India, susceptibility of Gram-negative bacteria to amikacin 
or ceftazidime has been reported as being only 68% and 
63%, respectively.107
Use of fluoroquinolone antibiotics has been widely dis-
cussed as a potential alternative to current antibiotic treatment 
Figure 4 Localized epiretinal infiltrates of fluffy creamy white appearance in Candida endophthalmitis.Clinical Ophthalmology 2010:4 128
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protocols. In particular, the recently developed third- and 
fourth-generation fluoroquinolones, such as levofloxacin 
and moxifloxacin, with their enhanced activity against 
Gram-positive pathogens, offer broad-spectrum activity that 
covers most organisms commonly encountered in bacterial 
endophthalmitis.108
Moxifloxacin, and fluoroquinolones in general, penetrate 
well into the eye. After topical administration at two-hourly 
intervals, moxifloxacin reaches mean aqueous concentrations 
of 2.3 µg/mL.109 A recent study demonstrated that anterior 
chamber levels achieved using moxifloxacin are higher than 
those obtained with any other topically administered fluoro-
quinolone antibiotic.109 Nevertheless, intravitreal concentra-
tions are 10 times lower than those in the anterior chamber. 
These levels are too low for effective treatment of intraocular 
infections.110 Systemic moxifloxacin does not exceed anterior 
chamber concentrations. It reaches intravitreal concentrations 
10 times higher than levels achieved by topical use, but to 
reach S. aureus and certain fluoroquinolone-resistant strains, 
higher concentrations are needed.111 Therefore, direct intra-
ocular application of such antibiotics seems useful.
Moxifloxacin is available as an unpreserved ophthal-
mic solution and covers both Gram-negative and -positive 
pathogens, including those most often implicated in the 
development of exogenous endophthalmitis.112 An addi-
tional potential advantage of moxifloxacin for intraocular 
use might be the administration of only a single substance 
into the eye.
Several studies have investigated the potential use of 
fourth-generation fluoroquinolones, and especially moxi-
floxacin, as prophylaxis for and treatment of endophthal-
mitis.113–119 In addition, pharmacokinetic data suggest 
intravitreal moxifloxacin is a useful alternative to current 
treatment protocols.120 Its safety has been demonstrated 
both in vivo and in vitro.113–117 An argument against use of 
moxifloxacin for the treatment of endophthalmitis may be 
that antibiotics from this group are widely used as topical 
antibiotics for treating superficial ocular infections and for 
preoperative prophylaxis. Moreover, concern exists about 
the emerging resistance of S. aureus and other Gram-positive 
isolates to third- and fourth-generation fluoroquinolones 
because of prophylactic use before and after intraocular 
surgery.53,121–123
These reports must be considered seriously, but it is 
noteworthy that sensitivity testing was determined in vitro 
and minimal inhibitory concentrations were based on serum 
levels (8 mg/mL). Recent data from toxicologic testing 
on ocular tissue indicate that moxifloxacin in doses up to 
150 µg/mL did not result in significant toxicity on several 
ocular cell types.113,114,116,117,124 Therefore, in vivo resistance 
appears to be very unlikely.
However, until these issues are resolved and its thera-
peutic role in endophthalmitis treatment is further eluci-
dated, moxifloxacin should only be used in combination 
with an agent that is more reliable against Gram-positive 
pathogens.
A potential use of moxifloxacin for intracameral endo-
phthalmitis prophylaxis in cataract surgery seems to be more 
reasonable. The ESCRS demonstrated that the prophylactic 
use of intracameral antibiotics helps to reduce the incidence 
of postoperative endophthalmitis after cataract surgery by 
75%.55 Therefore, prophylactic intracameral application of 
the β-lactam cefuroxime, together with the peptide antibiotic 
vancomycin, has become a beneficial and widely accepted 
practice for intracameral endophthalmitis prophylaxis in 
cataract surgery.125
However, in addition to the potential benefits, clini-
cians must consider that antibiotics from both groups are 
the mainstay of intravitreal treatment of endophthalmitis.7 
Consequently, one might argue that they should be reserved 
for this indication and not used for prophylaxis.
Due to its broad-spectrum properties, moxifloxacin is one 
of the most promising candidates in endophthalmitis pro-
phylaxis as an intracameral adjunct during cataract surgery. 
Nevertheless, further investigations will have to clarify the 
role of moxifloxacin in this context.
Systemic fluoroquinolones and antibiotics in general 
have been discussed as adjunctive systemic treatments for 
postoperative endophthalmitis. In 1995, the EVS evaluated 
the role of systemic antibiotics and pars plana vitrectomy in 
the treatment of postoperative endophthalmitis.7 The results 
of this study demonstrated that intravitreal antibiotics need 
not be supplemented with intravenous antibiotics in either 
acute or subacute postoperative endophthalmitis.7
Subconjunctival antibiotics may temporarily provide ther-
apeutic levels to the anterior segment but, in general, they do 
not penetrate sufficiently into the vitreous cavity.126 Further, 
large retrospective studies did not reveal an additional benefit 
compared with intravitreal antibiotic application.127,128
Corticosteroids are commonly used as adjunctive treat-
ment in bacterial as well in fungal endophthalmitis. These 
agents are given to modulate the inflammatory response 
to infection that might help to reduce secondary damage. 
Topical and subconjunctival steroids are widely accepted. 
However, use of steroids given via the systemic and intra-
vitreal routes in the treatment of endophthalmitis remains Clinical Ophthalmology 2010:4 129
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controversial. A prospective, randomized trial demonstrated 
significantly less inflammation in endophthalmitis cases 
after intervention when 400 µg dexamethasone was applied 
intravitreally.129 In contrast, visual outcome after 12 weeks 
was not affected.129 A recent study found a trend toward bet-
ter visual acuity with adjunctive dexamethasone in a smaller 
series of patients with endophthalmitis.130 Other studies did 
not find any significant effect on inflammation or visual 
acuity.131 Conversely, a retrospective, nonrandomized trial 
of 57 patients with postoperative endophthalmitis found a 
significantly worse visual outcome when intravitreal dexa-
methasone was added to therapy.132
Pars plana vitrectomy offers several potential benefits for 
endophthalmitis treatment. Results from the EVS showed 
that immediate vitrectomy provides a clear benefit in a well-
defined subgroup; patients with light perception only at the 
time of presentation had a significant, threefold improved 
chance of obtaining a visual acuity of 20/40 after vitrectomy.7 
For diabetic patients with hand movement or better vision, 
at least a trend toward better final visual acuity after vitrec-
tomy could be documented compared with vitreous tap and 
biopsy.7 One reason for this may be that vitrectomy results 
in a reduction of pathogens, toxins, inflammatory materials, 
and opacities. Furthermore, vitrectomy enables samples to 
be obtained for culture.
A potential disadvantage of vitrectomy in endophthalmi-
tis treatment might be that this technique is not ubiquitous 
and therefore effective treatment might be delayed. In addi-
tion, visualization of intraocular structures might be difficult, 
and vitrectomy might become desperate in highly inflamed 
eyes. Data from different studies are inconclusive, and the 
overall benefit of vitrectomy in endophthalmitis is still under 
discussion.7,133,134 However, the EVS addressed the relative 
effectiveness of immediate pars plana vitrectomy.7
One prognostic factor for the final visual outcome seems 
to be the type of infecting organism isolated and, in one 
study, if no or equivocal growth was detected in culture, 
80% of cases obtained a final visual acuity of 20/100 or 
  better.56 Infections with coagulase-negative staphylococci 
have also been associated with a final visual acuity of 20/100 
or better in the EVS population (84%).56 Due to their ability 
to induce significant inflammation, S. aureus, streptococci, 
and Gram-negative isolates seem to result in a worse visual 
outcome. Other strong predictors for poor visual outcome 
are initial visual acuity of light perception only, older age, 
corneal ring ulcers, compromised posterior capsule, abnormal 
intraocular pressure, afferent papillary defect, rubeosis iridis, 
and absence of the red fundus reflex.56
Endogenous endophthalmitis
In contrast with exogenous endophthalmitis, endogenous 
endophthalmitis requires systemic antimicrobial therapy. The 
primary source of infection in endogenous endophthalmitis 
is outside the eye, but within the body. Therefore, systemic 
cultures should be obtained.
Identification of the causative pathogen by blood, urine, 
or cerebrospinal fluid culture is successful in more than 
75% of endogenous endophthalmitis cases.3,4,135 Positive 
cultures from vitreous samples can be achieved much less 
frequently in endogenous endophthalmitis than in exog-
enous endophthalmitis.3,4,135 However, especially in fungal 
endophthalmitis, the value of obtaining an ocular culture 
should not be underestimated because it may be the sole 
source of microbial growth. In addition to cultures, in certain 
cases and for fastidious organisms, fungal/bacterial DNA in 
intraocular fluid can be detected by polymerase chain reac-
tion assay.136–138
The role of vitrectomy in endogenous endophthalmitis 
is not exactly defined. One reason for this could be that data 
from the EVS may not be applicable because the spectrum 
of causative organisms differs significantly in endogenous 
endophthalmitis. Although systemic and intravitreal anti-
biotics may be sufficient in milder forms of infection, vit-
rectomy seems to be helpful in severe cases of endogenous 
endophthalmitis because more virulent organisms, such as 
endotoxin-producing Streptococcus and Bacillus species, are 
commonly involved.3,4 In addition, material from vitrectomy 
may provide a better source for culturing.
Patients with endogenous endophthalmitis need to have 
the type and extent of their disease diagnosed, complica-
tions detected, and underlying systemic cause or risk factors 
defined. A major target of antimicrobial therapy in endog-
enous endophthalmitis treatment is the source of infection, 
which is often guided by culture and susceptibility of the 
infecting organism.
Systemic antimicrobial therapy is the mainstay of 
endogenous endophthalmitis treatment. In most cases, 
treatment is initiated empirically and the infecting organ-
ism presumed to be that causing systemic infection. For 
intravitreal antibiotic application in bacterial infections, 
as with exogenous endophthalmitis treatment, vanco-
mycin (1.0 mg/0.1 mL) for Gram-positive coverage or 
in combination with the β-lactam antibiotic ceftazidime 
(2.25 mg/0.1 mL) or amikacin (400 µg/0.1 mL) is recom-
mended for Gram-negative coverage. In general, systemic 
therapy must be continued for several weeks to ensure 
eradication of the infection.Clinical Ophthalmology 2010:4 130
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Fungal endophthalmitis
Only a small number of exogenous endophthalmitis cases are 
thought to be fungal. However, in some tropical countries, 
up to 50% of central corneal ulcers are caused by fungi,139–142 
and a recent review of more than 40 cases of exogenous 
fungal endophthalmitis revealed that almost 50% of these 
cases were associated with fungal keratitis.99 (see Figure 5). 
Therefore, exogenous fungal infections of the eye are of 
increasing concern.
If exogenous fungal endophthalmitis occurs, it is mostly 
caused by molds (mainly Fusarium and Aspergillus spe-
cies).99 Nevertheless, most cases of fungal endophthalmitis 
are a result of endogenous fungal spread into the eye. The 
most commonly reported causes of endogenous fungal 
endophthalmitis are Candida species (50%) followed by 
Aspergillus and Fusarium species.8,90,143–145
In endogenous fungal endophthalmitis, treatment should 
be instituted as soon as the diagnosis is made, under close 
supervision by the attending physician. Treatment guide-
lines for mild forms of fungal chorioretinitis and vitreitis 
suggest systemic antifungal therapy combined with serial 
ophthalmologic examinations.146,147 Surgical intervention 
combined with systemic and intraocular antifungal drug 
application is warranted in cases of moderate or severe 
  vitreous involvement.146,147
Most current treatment protocols recommend amphoteri-
cin B (5–10 µg/0.1 mL) and triazoles as primary therapeutic 
options. Both can be given systemically and intravitreally. 
However, the intraocular penetration of amphotericin B after 
topical or systemic treatment is limited, and intraocular use 
is associated with retinal toxicity.148 In addition, many fun-
gal pathogens affecting the human eye are not susceptible 
to these agents.90,143 Recently developed second-generation 
triazole derivates (eg, voriconazole) seem to be promising 
alternatives. Voriconazole can be given either systemically 
or intravitreally. It penetrates well into the ocular tissue after 
systemic administration.149 Severe systemic side effects seem 
to be less common than with amphotericin B and several in 
vitro studies indicate that the safety profile of voriconazole 
after intravitreal application may be superior to that of 
amphotericin B.150–154 The general in vitro susceptibility of 
Candida, Aspergillus, and Fusarium species to voriconazole 
are almost 100%.90 Numerous case reports indicate that vori-
conazole treatment has been successful where amphotericin 
B or fluconazole has failed, even in cases of drug-resistant 
fungal keratitis and endophthalmitis.152,155–160
Figure 5 Exogenous fungal endophthalmitis with corneal ulcer.Clinical Ophthalmology 2010:4 131
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In a situation where adequate and timely treatment is 
essential, eyes with endogenous fungal endophthalmitis may 
achieve a far better final visual acuity than eyes with bacte-
rial infections.6,161 In a larger series of endogenous fungal 
endophthalmitis cases, 65% of eyes achieved 20/400 or better 
acuity.2 Nevertheless, in endogenous fungal endophthalmi-
tis the organism isolated is critical for prognosis. Candida 
endophthalmitis seems to result in better outcomes than 
endoophthalmitis caused by Aspergillus or other fungi.2,5
Another potential treatment for endogenous fungal endo-
phthalmitis is caspofungin, the first member of a recently 
introduced new class of antifungal agents known as the 
echinocandins.162,163 Because of their different mechanism 
of action, these agents are an important therapeutic alterna-
tive to currently available antifungal treatments for invasive 
fungal infections. Caspofungin has potent antifungal activ-
ity against Candida and Aspergillus species, which are the 
predominant fungal pathogens in fungal endophthalmitis. 
Recent reports suggest that systemic caspofungin combined 
with voriconazole might be an effective treatment of endo-
phthalmitis caused by Candida, Acremonium, and Aspergillus 
species.159,164–166 However, the intraocular penetration prop-
erties of caspofungin after intravenous application remain 
unclear.167,168 One patient with advanced endogenous endo-
phthalmitis failed to respond to caspofungin, and after nine 
days of a standard systemic dosage, no caspofungin could 
be detected intravitreally.167
Clinical experience with caspofungin in endophthalmi-
tis treatment is limited. To date, no data are available on 
the potential intraocular use of caspofungin. First results 
from in vitro testing seem to be promising169 but need fur-
ther clarification in vivo. Nevertheless, due to their unique 
mechanism of action and their high activity against yeasts 
and mold, including those commonly affecting the eye,170–172 
caspofungin and other emerging drugs of this group might 
become more prominent in future treatment strategies for 
fungal endophthalmitis.
Conclusion
Endophthalmitis is one of the most devastating complications 
after ocular surgery or trauma and in people with systemic 
infection. Treatment of endophthalmitis remains challeng-
ing. Early diagnosis and treatment are essential to optimize 
visual outcome. Intravitreal antimicrobial drug application 
achieves the high intraocular substance levels needed for 
effective endophthalmitis treatment.
Vitrectomy seems to provide several substantial benefits 
in the treatment of endophthalmitis and remains accepted 
as a treatment option which is supplementary to intravitreal 
antimicrobial therapy in patients with moderate or severe 
disease. The EVS addressed the relative effectiveness of 
immediate pars plana vitrectomy after postoperative endo-
phthalmitis.7 However, a general advantage of vitrectomy in 
endophthalmitis is still under discussion.
In general, for exogenous endophthalmitis treatment, 
intravitreal antibiotics need not be supplemented with intra-
venous antibiotics. In contrast, most cases of endogenous 
endophthalmitis, where the primary focus of infection is 
outside the eye, require systemic antimicrobial therapy. 
Supplementary intravitreal drug application and vitrectomy 
may be supportive.
In fungal endophthalmitis, vitrectomy and intravitreal 
amphotericin B are indicated in case of severe vitreous 
involvement. Recent advances in therapy using antimycotic 
drugs, including the second-generation triazole agent vori-
conazole and the echinocandin caspofungin, may offer new 
treatment options to manage fungal endophthalmitis, but 
these drugs need further evaluation.
Disclosures
The authors do not have any commercial or financial interest 
in any of the materials or methods used in this study.
References
  1.  Mamalis N. Endophthalmitis. J Cataract Refract Surg. 2002;28(5): 
729–730.
  2.  Essman TF, Flynn HW Jr, Smiddy WE, et al. Treatment outcomes in a 
10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg 
Lasers. 1997;28(3):185–194.
  3.  Jackson TL, Eykyn SJ, Graham EM, Stanford MR. Endogenous bac-
terial endophthalmitis: 17-year prospective series and review of 267 
reported cases. Surg Ophthalmol. 2003;48(4):403–423.
  4.  Okada AA, Johnson RP, Liles WC, D’Amico DJ, Baker AS. Endog-
enous bacterial endophthalmitis. Report of a ten-year retrospective 
study. Ophthalmology. 1994;101(5):832–838.
  5.  Rao NA, Hidayat AA. Endogenous mycotic endophthalmitis: Variations 
in clinical and histopathologic changes in candidiasis compared with 
aspergillosis. Am J Ophthalmol. 2001;132(2):244–251.
  6.  Tanaka M, Kobayashi Y, Takebayashi H, Kiyokawa M, Qiu H. Analysis 
of predisposing clinical and laboratory findings for the development of 
endogenous fungal endophthalmitis. A retrospective 12-year study of 
79 eyes of 46 patients. Retina. 2001;21(3):203–209.
  7.  Results of the Endophthalmitis Vitrectomy Study. A randomized trial of 
immediate vitrectomy and of intravenous antibiotics for the treatment 
of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy 
Study Group. Arch Ophthalmol. 1995;113(12):1479–1496.
  8.  Essex RW, Yi Q, Charles PG, Allen PJ. Post-traumatic endophthalmitis. 
Ophthalmology. 2004;111(11):2015–2022.
  9.  Kattan HM, Flynn HW Jr, Pflugfelder SC, Robertson C, Forster RK. 
Nosocomial endophthalmitis survey. Current incidence of infection 
after intraocular surgery. Ophthalmology. 1991;98(2):227–238.
  10.  Aaberg TM Jr, Flynn HW Jr, Schiffman J, Newton J. Nosocomial 
acute-onset postoperative endophthalmitis survey. A 10-year review of 
incidence and outcomes. Ophthalmology. 1998;105(6):1004–1010.Clinical Ophthalmology 2010:4 132
Kernt and Kampik Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  11.  Bainbridge JW, Teimory M, Tabandeh H, et al. Intraocular lens 
implants and risk of endophthalmitis. Br J Ophthalmol. 1998;82(11): 
1312–1315.
  12.  Javitt JC, Street DA, Tielsch JM, et al. National outcomes of cataract 
extraction. Retinal detachment and endophthalmitis after outpatient 
cataract surgery. Cataract Patient Outcomes Research Team. Ophthal-
mology. 1994;101(1):100–105; discussion 106.
  13.  Mamalis N, Nagpal M, Nagpal K, Nagpal PN. Endophthalmitis   
following cataract surgery. Ophthalmol Clin North Am. 2001;14(4): 
661–674, ix.
  14.  Morlet N, Gatus B, Coroneo M. Patterns of peri-operative prophylaxis 
for cataract surgery: A survey of Australian ophthalmologists. Aust N 
Z J Ophthalmol. 1998;26(1):5–12.
  15.  Morlet N, Li J, Semmens J, Ng J. The Endophthalmitis Population 
Study of Western Australia (EPSWA): First report. Br J Ophthalmol. 
2003;87(5):574–576.
  16.  Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis 
following cataract surgery: A systematic review of the literature. Arch 
Ophthalmol. 2005;123(5):613–620.
  17.  Cooper BA, Holekamp NM, Bohigian G, Thompson PA. Case-control 
study of endophthalmitis after cataract surgery comparing scleral 
tunnel and clear corneal wounds. Am J Ophthalmol. 2003;136(2): 
300–305.
  18.  Nagaki Y, Hayasaka S, Kadoi C, et al. Bacterial endophthalmitis after 
small-incision cataract surgery. Effect of incision placement and intra-
ocular lens type. J Cataract Refract Surg. 2003;29(1):20–26.
  19.  Lalwani GA, Flynn HW Jr, et al. Acute-onset endophthalmitis 
after clear corneal cataract surgery (1996–2005). Clinical features, 
causative organisms, and visual acuity outcomes. Ophthalmology. 
2008;115(3):473–476.
  20.  Eifrig CW, Flynn HW Jr, Scott IU, Newton J. Acute-onset postoperative 
endophthalmitis: Review of incidence and visual outcomes (1995–
2001). Ophthalmic Surg Lasers. 2002;33(5):373–378.
  21.  Scott IU, Flynn HW Jr, Dev S, Shaikh S, Mittra RA, Arevalo JF, et al. 
Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: 
Incidence and outcomes. Retina. 2008;28(1):138–142.
  22.  Cantrill HL, Henry K, Melroe NH, Knobloch WH, Ramsay RC, 
Balfour HH Jr. Treatment of cytomegalovirus retinitis with intra-
vitreal ganciclovir. Long-term results. Ophthalmology. 1989;96(3): 
367–374.
  23.  Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitre-
ous injection: A comprehensive review. Retina. 2004;24(5):676–698.
  24.  Ciulla TA, Baker AS. Endophthalmitis following glaucoma filtering 
surgery. Int Ophthalmol Clin. 1996;36(3):87–96.
  25.  Al-Torbak AA, Al-Shahwan S, Al-Jadaan I, Al-Hommadi A, Edward DP. 
Endophthalmitis associated with the Ahmed glaucoma valve implant. 
Br J Ophthalmol. 2005;89(4):454–458.
  26.  Hassan SS, Wilhelmus KR, Dahl P, Davis GC, Roberts RT, Ross KW, 
et al. Infectious disease risk factors of corneal graft donors. Arch Oph-
thalmol. 2008;126(2):235–239.
  27.  Muckley ED, Lehrer RA. Late-onset blebitis/endophthalmitis: Inci-
dence and outcomes with mitomycin C. Optom Vis Sci. 2004;81(7): 
499–504.
  28.  Sharan S, Trope GE, Chipman M, Buys YM. Late-onset bleb infections: 
Prevalence and risk factors. Can J Ophthalmol. 2009;44(3):279–283.
  29.  Greenfield DS, Suner IJ, Miller MP, Kangas TA, Palmberg PF, Flynn 
HW Jr. Endophthalmitis after filtering surgery with mitomycin. Arch 
Ophthalmol. 1996;114(8):943–949.
  30.  Kangas TA, Greenfield DS, Flynn HW Jr, Parrish RK 2nd, Palmberg P. 
Delayed-onset endophthalmitis associated with conjunctival filtering 
blebs. Ophthalmology. 1997;104(5):746–752.
  31.  Song A, Scott IU, Flynn HW Jr, Budenz DL. Delayed-onset bleb-
associated endophthalmitis: Clinical features and visual acuity out-
comes. Ophthalmology. 2002;109(5):985–991.
  32.  Wolner B, Liebmann JM, Sassani JW, Ritch R, Speaker M, Marmor M. 
Late bleb-related endophthalmitis after trabeculectomy with adjunctive 
5-fluorouracil. Ophthalmology. 1991;98(7):1053–1060.
  33.  Higginbotham EJ, Stevens RK, Musch DC, Karp KO, Lichter PR, 
Bergstrom TJ, et al. Bleb-related endophthalmitis after trabeculectomy 
with mitomycin C. Ophthalmology. 1996;103(4):650–656.
  34.  Peponis V , Rosenberg P, Chalkiadakis SE, Insler M, Amariotakis A. 
Fungal scleral keratitis and endophthalmitis following pterygium exci-
sion. Eur J Ophthalmol. 2009;19(3):478–480.
  35.  Khurshid GS, Fahy GT. Endophthalmitis secondary to corneal sutures: 
Series of delayed-onset keratitis requiring intravitreal antibiotics. 
J Cataract Refract Surg. 2003;29(7):1370–1372.
  36.  Duker JS, Belmont JB. Late bacterial endophthalmitis following retinal 
detachment surgery. Retina. 1989;9(4):263–266.
  37.  Pathengay A, Karosekar S, Raju B, Sharma S, Das T. Microbiologic 
spectrum and susceptibility of isolates in scleral buckle infection in 
India. Am J Ophthalmol. 2004;138(4):663–664.
  38.  Recchia FM, Baumal CR, Sivalingam A, Kleiner R, Duker JS, 
Vrabec TR. Endophthalmitis after pediatric strabismus surgery. Arch 
Ophthalmol. 2000;118(7):939–944.
  39.  Proenca-Pina J, Ssi Yan Kai I, Bourcier T, Fabre M, Offret H, 
Labetoulle M. Fusarium keratitis and endophthalmitis associated with 
lens contact wear. Int Ophthalmol. 2010;30(1):103–107.
  40.  Lopez PF, Beldavs RA, al-Ghamdi S, Wilson LA, Wojno TH, Sternberg 
P Jr, et al. Pneumococcal endophthalmitis associated with nasolacrimal 
obstruction. Am J Ophthalmol. 1993;116(1):56–62.
  41.  Mino de Kaspar H, Shriver EM, Nguyen EV, et al. Risk factors 
for antibiotic-resistant conjunctival bacterial flora in patients 
  undergoing intraocular surgery. Graefes Arch Clin Exp Ophthalmol. 
2003;241(9):730–733.
  42.  Dortzbach RK, Woog JJ. Choice of procedure. Enucleation, evis-
ceration, or prosthetic fitting over globes. Ophthalmology. 1985;92(9): 
1249–1255.
  43.  Mino de Kaspar H, Grasbon T, Kampik A. Automated surgi-
cal equipment requires routine disinfection of vacuum control 
manifold to prevent postoperative endophthalmitis. Ophthalmology. 
2000;107(4):685–690.
  44.  Roy M, Chen JC, Miller M, Boyaner D, Kasner O, Edelstein E. Epidemic 
Bacillus endophthalmitis after cataract surgery I: Acute presentation 
and outcome. Ophthalmology. 1997;104(11):1768–1772.
  45.  Zaluski S, Clayman HM, Karsenti G, et al. Pseudomonas aeruginosa 
endophthalmitis caused by contamination of the internal fluid pathways 
of a phacoemulsifier. J Cataract Refract Surg. 1999;25(4):540–545.
  46.  Montan PG, Koranyi G, Setterquist HE, Stridh A, Philipson BT, 
Wiklund K. Endophthalmitis after cataract surgery: Risk factors relating 
to technique and events of the operation and patient history. A retrospec-
tive case-control study. Ophthalmology. 1998;105(12):2171–2177.
  47.  Schmitz S, Dick HB, Krummenauer F, Pfeiffer N. Endophthalmitis 
in cataract surgery: Results of a German survey. Ophthalmology. 
1999;106(10):1869–1877.
  48.  Gallenga PE, Mastropasqua L, Carpineto P, et al. In vitro Staphylococcus 
epidermidis growth in some viscoelastic substances containing sodium 
hyaluronate. Ophthalmologica. 1998;212(3):184–187.
  49.  Mastropasqua L, Piccolomini R, Carpineto P, et al. In vitro viability 
of external eye microbial flora in hydroxy-propyl-methylcellulose. 
Ophthalmologica. 1999;213(4):265–268.
  50.  Mamalis N, Kearsley L, Brinton E. Postoperative endophthalmitis. Curr 
Opin Ophthalmol. 2002;13(1):14–18.
  51.  Breitbach R, Spitznas M. Perioperative risk of infection in cataract 
surgery. Klin Monatsbl Augenheilkd. 1991;198(2):94–98.
  52.  Meredith TA, Trabelsi A, Miller MJ, Aguilar E, Wilson LA. Spon-
taneous sterilization in experimental Staphylococcus epidermidis 
endophthalmitis. Invest Ophthalmol Vis Sci. 1990;31(1):181–186.
  53.  Kunimoto DY, Das T, Sharma S, et al. Microbiologic spectrum 
and susceptibility of isolates: Part I. Postoperative endophthalmitis. 
  Endophthalmitis Research Group. Am J Ophthalmol. 1999;128(2): 
240–242.
  54.  Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmi-
tis following intravitreal triamcinolone acetonide injection. Am J 
  Ophthalmol. 2003;136(5):791–796.Clinical Ophthalmology 2010:4 133
Clinical aspects of endophthalmitis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  55.  Prophylaxis of postoperative endophthalmitis following cataract 
  surgery: Results of the ESCRS multicenter study and identification of 
risk factors. J Cataract Refract Surg. 2007;33(6):978–988.
  56.  No authors listed. Microbiologic factors and visual outcome in the 
endophthalmitis vitrectomy study. Am J Ophthalmol. 1996;122(6): 
830–846.
  57.  Mao LK, Flynn HW Jr, Miller D, Pflugfelder SC. Endophthalmitis 
caused by streptococcal species. Arch Ophthalmol. 1992;110(6): 
798–801.
  58.  Miller JJ, Scott IU, Flynn HW Jr, Smiddy WE, Corey RP, Miller D. 
Endophthalmitis caused by Streptococcus pneumoniae. Am J Ophthalmol. 
2004;138(2):231–236.
  59.  Soriano F, Perez-Trallero E, Pallares R, et al. Streptococcus pneu-
moniae endophthalmitis: A study of 36 cases with special reference 
to antibiotic resistance and treatment options. Clin Microbiol Infect. 
2006;12(6):519–526.
  60.  Pinna A, Sechi LA, Zanetti S, Delogu D, Carta F. Adherence of ocular 
isolates of staphylococcus epidermidis to ACRYSOF intraocular 
lenses. A scanning electron microscopy and molecular biology study. 
Ophthalmology. 2000;107(12):2162–2166.
  61.  Pinna A, Zanetti S, Sechi LA, Usai D, Falchi MP, Carta F. In vitro 
adherence of Staphylococcus epidermidis to polymethyl methacrylate 
and ACRYSOF intraocular lenses. Ophthalmology. 2000;107(6): 
1042–1046.
  62.  Affeldt JC, Flynn HW Jr, Forster RK, Mandelbaum S, Clarkson JG, 
Jarus GD. Microbial endophthalmitis resulting from ocular trauma. 
Ophthalmology. 1987;94(4):407–413.
  63.  Brinton GS, Topping TM, Hyndiuk RA, Aaberg TM, Reeser FH, 
Abrams GW. Posttraumatic endophthalmitis. Arch Ophthalmol. 
1984;102(4):547–550.
  64.  Kresloff MS, Castellarin AA, Zarbin MA. Endophthalmitis. Surv 
Ophthalmol. 1998;43(3):193–224.
  65.  Chaudhry IA, Shamsi FA, Al-Harthi E, Al-Theeb A, Elzaridi E, 
Riley FC. Incidence and visual outcome of endophthalmitis associated 
with intraocular foreign bodies. Graefes Arch Clin Exp Ophthalmol. 
2008;246(2):181–186.
  66.  Ariyasu RG, Kumar S, LaBree LD, Wagner DG, Smith RE. 
  Microorganisms cultured from the anterior chamber of ruptured globes 
at the time of repair. Am J Ophthalmol. 1995;119(2):181–188.
  67.  Rubsamen PE, Cousins SW, Martinez JA. Impact of cultures on 
  management decisions following surgical repair of penetrating ocular 
trauma. Ophthalmic Surg Lasers. 1997;28(1):43–49.
  68.  Thompson JT, Parver LM, Enger CL, Mieler WF, Liggett PE. 
  Infectious endophthalmitis after penetrating injuries with retained intra-
ocular foreign bodies. National Eye Trauma System. Ophthalmology. 
1993;100(10):1468–1474.
  69.  Thompson WS, Rubsamen PE, Flynn HW Jr, Schiffman J, Cousins SW. 
Endophthalmitis after penetrating trauma. Risk factors and visual acuity 
outcomes. Ophthalmology. 1995;102(11):1696–1701.
  70.  Zhang Y, Zhang M, Jiang C, Yao Y, Zhang K. Endophthalmitis fol-
lowing open globe Injury. Br J Ophthalmol. Epub ahead of print. 2009 
Aug 18.
  71.  Hooi SH, Hooi ST. Open-globe injuries: The experience at Hospi-
tal Sultanah Aminah, Johor Bahru. Med J Malaysia. 2003;58(3): 
405–412.
  72.  Sabaci G, Bayer A, Mutlu FM, Karagul S, Yildirim E. Endophthalmitis 
after deadly-weapon-related open-globe injuries: Risk factors, value 
of prophylactic antibiotics, and visual outcomes. Am J Ophthalmol. 
2002;133(1):62–69.
  73.  Schrader WF. Epidemiology of open globe eye injuries: Analysis 
of 1026 cases in 18 years. Klin Monbl Augenheilkd. 2004;221(8): 
629–635.
  74.  Alfaro DV , Roth DB, Laughlin RM, Goyal M, Liggett PE. Paediat-
ric post-traumatic endophthalmitis. Br J Ophthalmol. 1995;79(10): 
888–891.
  75.  Verbraeken H, Rysselaere M. Post-traumatic endophthalmitis. Eur J 
Ophthalmol. 1994;4(1):1–5.
  76.  Williams DF, Mieler WF, Abrams GW, Lewis H. Results and prognostic 
factors in penetrating ocular injuries with retained intraocular foreign 
bodies. Ophthalmology. 1988;95(7):911–916.
  77.  Bohigian GM, Olk RJ. Factors associated with a poor visual result in 
endophthalmitis. Am J Ophthalmol. 1986;101(3):332–341.
  78.  Ness T, Pelz K. Endophthalmitis: Improvement of culture results. 
Ophthalmologe. 2000;97(1):33–37.
  79.  Chee SP, Jap A. Endogenous endophthalmitis. Curr Opin Ophthalmol. 
2001;12(6):464–470.
  80.  Shrader SK, Band JD, Lauter CB, Murphy P. The clinical spectrum of 
endophthalmitis: Incidence, predisposing factors, and features influenc-
ing outcome. J Infect Dis. 1990;162(1):115–120.
  81.  Brod RD, Flynn HW Jr, Clarkson JG, Pflugfelder SC, Culbertson WW, 
Miller D. Endogenous Candida endophthalmitis. Management without 
intravenous amphotericin B. Ophthalmology. 1990;97(5):666–672; 
discussion 672–674.
  82.  Nakayama F, Soloway RD, Nakama T, et al. Hepatolithiasis in East 
Asia. Retrospective study. Dig Dis Sci. 1986;31(1):21–26.
  83.  Wong JS, Chan TK, Lee HM, Chee SP. Endogenous bacterial endo-
phthalmitis: An east Asian experience and a reappraisal of a severe 
ocular affliction. Ophthalmology. 2000;107(8):1483–1491.
  84.  Chen YJ, Kuo HK, Wu PC, et al. A 10-year comparison of endogenous 
endophthalmitis outcomes: An east Asian experience with Klebsiella 
pneumoniae infection. Retina. 2004;24(3):383–390.
  85.  Ness T, Pelz K, Hansen LL. Endogenous endophthalmitis: Micro-
organisms, disposition and prognosis. Acta Ophthalmol Scand. 
2007;85(8):852–856.
  86.  Sallam A, Lynn W, McCluskey P, Lightman S. Endogenous Candida 
endophthalmitis. Expert Rev Anti Infect Ther. 2006;4(4):675–685.
  87.  Chen YC, Chang SC, Luh KT, Hsieh WC. Stable susceptibility of 
Candida blood isolates to fluconazole despite increasing use during 
the past 10 years. J Antimicrob Chemother. 2003;52(1):71–77.
  88.  Kibbler CC, Seaton S, Barnes RA, et al. Management and outcome of 
bloodstream infections due to Candida species in England and Wales. 
J Hosp Infect. 2003;54(1):18–24.
  89.  Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities 
of fluconazole and voriconazole against 1,586 recent clinical isolates 
of Candida species determined by Broth microdilution, disk diffusion, 
and Etest methods: Report from the ARTEMIS Global Antifungal Sus-
ceptibility Program, 2001. J Clin Microbiol. 2003;41(4):1440–1446.
  90.  Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation 
of voriconazole susceptibility for keratitis and endophthalmitis fungal 
pathogens. Am J Ophthalmol. 2004;137(5):820–825.
  91.  Kostick DA, Foster RE, Lowder CY, Meyers SM, McHenry MC. 
Endogenous endophthalmitis caused by Candida albicans in a healthy 
woman. Am J Ophthalmol. 1992;113(5):593–595.
  92.  Brooks RG. Prospective study of Candida endophthalmitis in hos-
pitalized patients with candidemia. Arch Intern Med. 1989;149(10): 
2226–2228.
  93.  Krishna R, Amuh D, Lowder CY, Gordon SM, Adal KA, Hall G. Should 
all patients with candidaemia have an ophthalmic examination to rule 
out ocular candidiasis? Eye. 2000;14(Pt 1):30–34.
  94.  Feman SS, Nichols JC, Chung SM, Theobald TA. Endophthalmitis in 
patients with disseminated fungal disease. Trans Am Ophthalmol Soc. 
2002;100:67–70; discussion 70–71.
  95.  Pappas PG, Rex JH, Lee J, et al. A prospective observational study 
of candidemia: Epidemiology, therapy, and influences on mortality in 
hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37(5): 
634–643.
  96.  Donahue SP, Greven CM, Zuravleff JJ, et al. Intraocular candidiasis 
in patients with candidemia. Clinical implications derived from 
a prospective multicenter study. Ophthalmology. 1994;101(7): 
1302–1309.
  97.  Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, 
Rex JH. Retinal lesions as clues to disseminated bacterial and candidal 
infections: Frequency, natural history, and etiology. Medicine (Baltimore). 
2003;82(3):187–202.Clinical Ophthalmology 2010:4 134
Kernt and Kampik Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  98.  Maguire JI. Postoperative endophthalmitis: Optimal management 
and the role and timing of vitrectomy surgery. Eye (Lond). 
2008;22(10):1290–1300.
  99.  Wykoff CC, Flynn HW Jr, Miller D, Scott IU, Alfonso EC. Exogenous 
fungal endophthalmitis: Microbiology and clinical outcomes. Oph-
thalmology. 2008;115(9):1501–1507.
  100.  Jackson TL, Williamson TH. Amikacin retinal toxicity. Br J 
Ophthalmol. 1999;83(10):1199–1200.
  101.  Seawright AA, Bourke RD, Cooling RJ. Macula toxicity after intra-
vitreal amikacin. Aust N Z J Ophthalmol. 1996;24(2):143–146.
  102.  Recchia FM, Busbee BG, Pearlman RB, Carvalho-Recchia CA, 
Ho AC. Changing trends in the microbiologic aspects of postcataract 
endophthalmitis. Arch Ophthalmol. 2005;123(3):341–346.
  103.  Bains HS, Weinberg DV, Feder RS, Noskin GA. Postoperative 
vancomycin-resistant Enterococcus faecium endophthalmitis. Arch 
Ophthalmol. 2007;125(9):1292–1293.
  104.  Esmaeli  B,  Holz  ER, Ahmadi  MA,  Krathen  RA,  Raad  II. 
Endogenous endophthalmitis secondary to vancomycin-resistant 
  enterococciinfection. Retina. 2003;23(1):118–119.
  105.  Nucci C, Artini M, Pasmore M, Missiroli F, Costerton JW, Selan L. 
A microbiological and confocal microscopy study documenting a 
slime-producing Staphylococcus epidermidis isolated from a nylon 
corneal suture of a patient with antibiotic-resistant endophthalmitis. 
Graefes Arch Clin Exp Ophthalmol. 2005;243(9):951–954.
  106.  Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin 
resistance in Staphylococcus aureus. Glycopeptide-Intermediate 
Staphylococcus aureus Working Group. N Engl J Med. 1999;340(7): 
493–501.
  107.  Anand AR, Therese KL, Madhavan HN. Spectrum of aetiological 
agents of postoperative endophthalmitis and antibiotic susceptibility 
of bacterial isolates. Indian J Ophthalmol. 2000;48(2):123–128.
  108.  Callegan MC, Ramirez R, Kane ST, Cochran DC, Jensen H. Antibac-
terial activity of the fourth-generation fluoroquinolones gatifloxacin 
and moxifloxacin against ocular pathogens. Adv Ther. 2003;20(5): 
246–252.
  109.  McCulley JP, Caudle D, Aronowicz JD, Shine WE. Fourth-generation 
fluoroquinolone penetration into the aqueous humor in humans. Oph-
thalmology. 2006;113(6):955–959.
  110.  Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharma-
cokinetics of topically administered 0.5% moxifloxacin ophthal-
mic solution in human aqueous and vitreous. Arch Ophthalmol. 
2005;123(1):39–44.
  111.  Gao H, Pennesi ME, Qiao X, et al. Intravitreal moxifloxacin: Retinal 
safety study with electroretinography and histopathology in animal 
models. Invest Ophthalmol Vis Sci. 2006;47(4):1606–1611.
  112.  Kernt M, Hirneiss C, Neubauer AS, Liegl RG, Eibl KH, Wolf A, 
et al. Intracameral moxifloxacin: A safe option for endophthalmitis 
prophylaxis? : In vitro safety profile for intraocular application. Oph-
thalmologe. Epub ahead of print 2009 Sep 17.
  113.  Ermis SS, Cetinkaya Z, Kiyici H, Inan UU, Ozturk F. Effects 
of intravitreal moxifloxacin and dexamethasone in experimen-
tal Staphylococcus aureus endophthalmitis.  Curr Eye Res. 
2007;32(4):337–344.
  114.  Ermis SS, Cetinkaya Z, Kiyici H, Ozturk F. Treatment of Staphylococ-
cus epidermidis endophthalmitis with intravitreal moxifloxacin in a 
rabbit model. Tohoku J Exp Med. 2005;205(3):223–229.
  115.  Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and 
moxifloxacin: An in vitro susceptibility comparison to levofloxacin, 
ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J 
Ophthalmol. 2003;136(3):500–505.
  116.  Kernt M, Neubauer AS, Liegl RG, et al. Intracameral moxifloxacin: 
In vitro safety on human ocular cells. Cornea. 2009;28(5):553–561.
  117.  Kernt M, Neubauer AS, Ulbig MW, Kampik A, Welge-Lussen U. 
In vitro safety of intravitreal moxifloxacin for endophthalmitis treat-
ment. J Cataract Refract Surg. 2008;34(3):480–488.
  118.  Lott MN, Fuller JJ, Hancock HA, et al. Vitreal penetration of oral 
moxifloxacin in humans. Retina. 2008;28(3):473–476.
  119.  Yagci R, Oflu Y, Dincel A, et al. Penetration of second-, third-, 
and fourth-generation topical fluoroquinolone into aqueous and 
vitreous humour in a rabbit endophthalmitis model. Eye (Lond). 
2007;21(7):990–994.
  120.  Iyer MN, He F, Wensel TG, Mieler WF, Benz MS, Holz ER. 
Intravitreal clearance of moxifloxacin. Trans Am Ophthalmol Soc. 
2005;103:76–81; discussion 81–83.
  121.  Deramo VA, Lai JC, Fastenberg DM, Udell IJ. Acute endophthalmitis 
in eyes treated prophylactically with gatifloxacin and moxifloxacin. 
Am J Ophthalmol. 2006;142(5):721–725.
  122.  Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone 
resistance in bacterial keratitis: A 5-year review. Ophthalmology. 
1999;106(7):1313–1318.
  123.  Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of 
bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. 
Ophthalmology. 1999;106(1):80–805.
  124.  Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. 
Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective 
in preventing endophthalmitis in a rabbit model. Am J Ophthalmol. 
2005;140(3):497–504.
  125.  Masket S. Preventing, diagnosing, and treating endophthalmitis. 
J Cataract Refract Surg. 1998;24(6):725–726.
  126.  Barza M, Doft B, Lynch E. Ocular penetration of ceftriaxone, cef-
tazidime, and vancomycin after subconjunctival injection in humans. 
Arch Ophthalmol. 1993;111(4):492–494.
  127.  Iyer MN, Han DP, Yun HJ, et al. Subconjunctival antibiotics for 
acute postcataract extraction endophthalmitis – is it necessary? Am J 
Ophthalmol. 2004;137(6):1120–1121.
  128.  Smiddy WE, Smiddy RJ, Ba’Arath B, et al. Subconjunctival antibiot-
ics in the treatment of endophthalmitis managed without vitrectomy. 
Retina. 2005;25(6):751–758.
  129.  Das T, Jalali S, Gothwal VK, Sharma S, Naduvilath TJ. Intravitreal 
dexamethasone in exogenous bacterial endophthalmitis: Results 
of a prospective randomised study. Br J Ophthalmol. 1999;83(9): 
1050–1055.
  130.  Gan IM, Ugahary LC, van Dissel JT, et al. Intravitreal dexametha-
sone as adjuvant in the treatment of postoperative endophthalmitis: 
A prospective randomized trial. Graefes Arch Clin Exp Ophthalmol. 
2005;243(12):1200–1205.
  131.  Hall EF, Scott GR, Musch DC, Zacks DN. Adjunctive intravitreal 
dexamethasone in the treatment of acute endophthalmitis following 
cataract surgery. Clin Ophthalmol. 2008;2(1):139–145.
  132.  Shah GK, Stein JD, Sharma S, Sivalingam A, et al. Visual out-
comes following the use of intravitreal steroids in the treatment 
of postoperative endophthalmitis. Ophthalmology. 2000;107(3): 
486–489.
  133.  Doft BH, Kelsey SF, Wisniewski SR. Additional procedures after the 
initial vitrectomy or tap-biopsy in the Endophthalmitis Vitrectomy 
Study. Ophthalmology. 1998;105(4):707–716.
  134.  Kuhn F, Gini G. Ten years after ... are findings of the Endophthal-
mitis Vitrectomy Study still relevant today? Graefes Arch Clin Exp 
  Ophthalmol. 2005;243(12):1197–1199.
  135.  Greenwald MJ, Wohl LG, Sell CH. Metastatic bacterial endophthal-
mitis: A contemporary reappraisal. Surv Ophthalmol. 1986;31(2): 
81–101.
  136.  Jaeger EE, Carroll NM, Choudhury S, et al. Rapid detection and 
identification of Candida, Aspergillus, and Fusarium species in 
ocular samples using nested PCR. J Clin Microbiol. 2000;38(8): 
2902–2908.
  137.  Lohmann CP, Linde HJ, Reischl U. Improved detection of microorgan-
isms by polymerase chain reaction in delayed endophthalmitis after 
cataract surgery. Ophthalmology. 2000;107(6):1047–1051; discussion 
1051–1052.
  138.  Okhravi N, Adamson P, Carroll N, et al. PCR-based evidence of 
bacterial involvement in eyes with suspected intraocular infection. 
Invest Ophthalmol Vis Sci. 2000;41(11):3474–3479.Clinical Ophthalmology 2010:4
Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
135
Clinical aspects of endophthalmitis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
  139.  Dunlop AA, Wright ED, Howlader SA, et al. Suppurative corneal 
ulceration in Bangladesh. A study of 142 cases examining the micro-
biological diagnosis, clinical and epidemiological features of bacterial 
and fungal keratitis. Aust NZ J Ophthalmol. 1994;22(2):105–110.
  140.  Polack FM, Kaufman HE, Newmark E. Keratomycosis. Medical and 
surgical treatment. Arch Ophthalmol. 1971;85(4):410–416.
  141.  Srinivasan M, Gonzales CA, George C, et al. Epidemiology and 
aetiological diagnosis of corneal ulceration in Madurai, south India. 
Br J Ophthalmol. 1997;81(11):965–971.
  142.  Thomas PA. Mycotic keratitis – an underestimated mycosis. J Med 
Vet Mycol. 1994;32(4):235–256.
  143.  Benz MS, Scott IU, Flynn HW Jr, Unonius N, Miller D. Endophthal-
mitis isolates and antibiotic sensitivities: A 6-year review of culture-
proven cases. Am J Ophthalmol. 2004;137(1):38–42.
  144.  Keswani T, Ahuja V , Changulani M. Evaluation of outcome of various 
treatment methods for endogenous endophthalmitis. Indian J Med Sci. 
2006;60(11):454–460.
  145.  Narang S, Gupta A, Gupta V , et al. Fungal endophthalmitis following 
cataract surgery: Clinical presentation, microbiological spectrum, and 
outcome. Am J Ophthalmol. 2001;132(5):609–617.
  146.  Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of 
candidiasis. Clin Infect Dis. 2004;38(2):161–189.
  147.  Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines 
for the management of candidiasis: 2009 update by the Infectious 
Diseases Society of America. Clin Infect Dis. 2009;48(5):503–535.
  148.  Axelrod AJ, Peyman GA, Apple DJ. Toxicity of intravitreal injection 
of amphotericin B. Am J Ophthalmol. 1973;76(4):578–583.
  149.  Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, 
aqueous, and plasma concentration of orally administered voriconazole 
in humans. Arch Ophthalmol. 2004;122(1):42–47.
  150.  Herbrecht R. Voriconazole: Therapeutic review of a new azole 
  antifungal. Expert Rev Anti Infect Ther. 2004;2(4):485–497.
  151.  Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: 
An electroretinographic and histopathologic study. Arch Ophthalmol. 
2004;122(11):1687–1692.
  152.  Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D. 
Intravitreal voriconazole for the treatment of endogenous Aspergillus 
endophthalmitis. Ophthalmology. 2006;113(7):1184–1186.
  153.  Kernt M, Kampik A. Intracameral voriconazole: In vitro safety for 
human ocular cells. Toxicology. 2009;258(2–3):84–93.
  154.  Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal vori-
conazole: In vitro safety-profile for fungal endophthalmitis. Retina. 
2009;29(3):362–370.
  155.  Bunya VY, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ. 
Topical and oral voriconazole in the treatment of fungal keratitis. Am J 
Ophthalmol. 2007;143(1):151–153.
  156.  Creti A, Esposito V , Bocchetti M, et al. Voriconazole curative treat-
ment for Acremonium species keratitis developed in a patient with 
concomitant Staphylococcus aureus corneal infection: A case report. 
In Vivo. 2006;20(1):169–171.
  157.  Freda R. Use of oral voriconazole as adjunctive treatment of 
severe cornea fungal infection: Case report. Arq Bras Oftalmol. 
2006;69(3):431–434.
  158.  Ozbek Z, Kang S, Sivalingam J, Rapuano CJ, Cohen EJ, Hammersmith KM. 
Voriconazole in the management of Alternaria keratitis. Cornea. 
2006;25(2):242–244.
  159.  Durand ML, Kim IK, D’Amico DJ, et al. Successful treatment 
of Fusarium endophthalmitis with voriconazole and Aspergillus   
endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol. 
2005;140(3):552–554.
  160.  Nehemy MB, Vasconcelos-Santos DV , Torqueti-Costa L, Magalhaes EP. 
Chronic endophthalmitis due to verticillium species after cataract 
surgery treated (or managed) with pars plana vitrectomy and oral and 
intravitreal voriconazole. Retina. 2006;26(2):225–227.
  161.  Binder MI, Chua J, Kaiser PK, Procop GW, Isada CM. Endogenous 
endophthalmitis: An 18-year review of culture-positive cases at a 
tertiary care center. Medicine (Baltimore). 2003;82(2):97–105.
  162.  Agarwal MB, Rathi SA, Ratho N, Subramanian R. Caspofungin: 
Major breakthrough in treatment of systemic fungal infections. J Assoc 
Physicians India. 2006;54:943–948.
  163.  Theuretzbacher U. Pharmacokinetics/pharmacodynamics of 
  echinocandins. Eur J Clin Microbiol Infect Dis. 2004;23(11): 
805–812.
  164.  Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. 
Management of endogenous fungal endophthalmitis with voriconazole 
and caspofungin. Am J Ophthalmol. 2005;139(1):135–140.
  165.  Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: 
  Caspofungin. Mycoses. 2002;45 Suppl 3:56–60.
  166.  Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, 
Vidal AM. Candida glabrata endophthalmitis treated successfully with 
caspofungin. Clin Infect Dis. 2005;40(5):e46–e48.
  167.  Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular 
penetration of caspofungin and associated treatment failure in Candida 
albicans endophthalmitis. Clin Infect Dis. 2005;41(3):e27–e28.
  168.  Goldblum D, Fausch K, Frueh BE, Theurillat R, Thormann W, 
  Zimmerli S. Ocular penetration of caspofungin in a rabbit uveitis 
model. Graefes Arch Clin Exp Ophthalmol. 2007;245(6):825–833.
  169.  Kernt M, Hirneiss C, Neubauer AS, et al. Intracameral moxifloxacin: 
A safe option for endophthalmitis prophylaxis? In vitro safety profile 
for intraocular application. Ophthalmologe. Epub ahead of print 
2009 sep 17.
  170.  Espinel-Ingroff A. Comparison of in vitro activities of the new 
  triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and 
LY303366 against opportunistic filamentous and dimorphic fungi and 
yeasts. J Clin Microbiol. 1998;36(10):2950–2956.
  171.  Klepser ME, Ernst EJ, Ernst ME, Messer SA, Pfaller MA. Evalu-
ation of endpoints for antifungal susceptibility determinations 
with LY303366. Antimicrob Agents Chemother. 1998;42(6): 
1387–1391.
  172.  Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two 
echinocandin derivatives, LY303366 and MK-0991 (L-743,792), 
against clinical isolates of Aspergillus, Fusarium, Rhizopus, and 
other filamentous fungi. Diagn Microbiol Infect Dis. 1998;30(4): 
251–255.